Nakashima S, Arai S, Mizuno Y, Yoshino K, Ando S, Nakamura Y, Sugawara K, Koike M, Saito E, Naito M, Nakao M, Ito H, Hamaoka K, Rai F, Asakura Y, Akamatu M, Fujimori K, Inao M, Imai Y, Ota S, Fujiwara K, Shiibashi M
Department of Gastroenterology & Hepatology, Saitama Medical School, Iruma-gun, Saitama, Japan.
Aliment Pharmacol Ther. 2005 Jun;21 Suppl 2:60-6. doi: 10.1111/j.1365-2036.2005.02476.x.
The incidence and severity of non-steroidal anti-inflammatory drugs (NSAIDs)-induced gastro-duodenal ulcer have not been extensively studied in Japan.
We performed a prospective study to clarify NSAIDs-induced gastro-duodenal injury, focusing especially on low-dose aspirin (L-A).
Two hundred and thirty-eight patients with bleeding peptic ulcers admitted to our hospital. History of taking NSAIDs and anti-ulcer drugs was obtained from all patients who underwent endoscopic examinations. The lesion scores of patients taking L-A were classified numerically from zero (no lesion) to five (ulcer).
The NSAIDs were associated with 28.2% of hemorrhagic ulcers. The rates of patients using L-A, loxoprofen, diclofenac, and combination of two of these drugs were 27, 16, 10 and 9%, respectively. Co-administered anti-ulcer drugs were cytoprotective anti-ulcer drugs (27%), H2 receptor antagonists (16%), PPI (4%), and none (53%). In patients taking L-A, H2 receptor antagonists were used most frequently. The HP was positive in 63% of L-A-induced ulcer cases and in 69% of NSAIDs other than low-dose aspirin-induced ulcer cases. The lesion scores of patients taking L-A with H2 receptor antagonists or PPI were significantly lower than those of patients who were taking only L-A (P < 0.05).
Approximately one-third of hospitalized patients with NSAIDs-induced hemorrhagic ulcer showed an association with L-A. Prospective randomized controlled trials including H2 receptor antagonists are required to establish preventive efforts aimed at L-A-induced gastro-duodenal injury.
在日本,非甾体类抗炎药(NSAIDs)引起的胃十二指肠溃疡的发病率和严重程度尚未得到广泛研究。
我们进行了一项前瞻性研究,以阐明NSAIDs引起的胃十二指肠损伤,尤其关注低剂量阿司匹林(L-A)。
238例因消化性溃疡出血入住我院的患者。对所有接受内镜检查的患者获取服用NSAIDs和抗溃疡药物的病史。服用L-A患者的病变评分从0(无病变)到5(溃疡)进行数字分类。
NSAIDs与28.2%的出血性溃疡相关。使用L-A、洛索洛芬、双氯芬酸以及这两种药物联用的患者比例分别为27%、16%、10%和9%。联合使用的抗溃疡药物有细胞保护类抗溃疡药物(27%)、H2受体拮抗剂(16%)、质子泵抑制剂(PPI,4%)以及未使用任何药物(53%)。在服用L-A的患者中,最常使用H2受体拮抗剂。在L-A引起的溃疡病例中,63%幽门螺杆菌(HP)呈阳性,在低剂量阿司匹林以外的NSAIDs引起的溃疡病例中,69% HP呈阳性。服用L-A并使用H2受体拮抗剂或PPI的患者的病变评分显著低于仅服用L-A的患者(P < 0.05)。
约三分之一因NSAIDs引起出血性溃疡而住院的患者与L-A有关。需要开展包括H2受体拮抗剂的前瞻性随机对照试验,以确立针对L-A引起的胃十二指肠损伤的预防措施。